EverydayHealthLogo
Dr. Yasodha Natkunam, MD, PHD

Dr. Yasodha Natkunam, MD, PHD

Pleasanton, CA

24 Years of Experience

Accepting patients

Affiliated with a Castle Connolly Top Hospital

    Who is Dr. Natkunam, Anatomic Pathologist & Clinical Pathologist in Pleasanton, CA?

    Dr. Yasodha Natkunam, MD, PHD is an Anatomic Pathologist & Clinical Pathologist, who primarily practices in Pleasanton, CA with 1 additional practice location. She has been practicing for over 24 years and is board certified. Dr. Natkunam graduated from Icahn School of Medicine at Mount Sinai and completed her residency at Stanford University Program. Dr. Natkunam is fluent in English and Tamil, and is currently seeing new patients. Dr. Natkunam’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Natkunam’s office at (650) 723-7211.

    Where did Dr. Natkunam go to medical school and complete their residency?

    • Residency: Stanford University Program

    • Medical School: Icahn School of Medicine at Mount Sinai

    Is Dr. Natkunam board certified as an Anatomic Pathologist & Clinical Pathologist?

    Yes, Dr. Yasodha Natkunam, MD, PHD is board certified by the American Board of Pathology since 1998

    What languages does Dr. Natkunam speak?

    Dr. Natkunam and their clinical team can communicate with patients in the following languages:

    • English

    • Tamil

    What conditions does an Anatomic Pathologist & Clinical Pathologist like Dr. Natkunam typically treat?

    As an Anatomic Pathologist & Clinical Pathologist, Dr. Natkunam diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Natkunam. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.

    Also known as:

    • Multiple Myeloma
    • Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
    • Active multiple myeloma
    • Untreated multiple myeloma
    • Plasma cell myeloma

    ICD-10 Codes:

    • C9000: Multiple myeloma not having achieved remission

    Also known as:

    • Diffuse Large B-cell Lymphoma
    • Lymphoma
    • DLBCL
    • Aggressive B-cell Lymphoma
    • Diffuse B-cell Lymphoma

    ICD-10 Codes:

    • C8330: Diffuse large B-cell lymphoma, unspecified site
    • C8339: Diffuse large B-cell lymphoma, extranodal and solid organ sites
    • C83398: Diffuse large B-cell lymphoma of other extranodal and solid organ sites

    Also known as:

    • Localized Swollen Lymph Nodes
    • Widespread Swollen Lymph Nodes
    • Enlarged glands in one area
    • Local lymphadenopathy
    • Swollen glands
    • Generalized lymphadenopathy
    • Multiple swollen glands
    • Body-wide enlarged lymph nodes

    ICD-10 Codes:

    • R590: Localized enlarged lymph nodes
    • R591: Generalized enlarged lymph nodes

    Also known as:

    • Acute Myeloid Leukemia
    • AML Leukemia
    • Acute Myeloblastic Leukemia
    • Acute Myelogenous Leukemia

    ICD-10 Codes:

    • C9200: Acute myeloblastic leukemia, not having achieved remission

    Also known as:

    • Myelodysplastic Syndrome
    • Myelodysplastic Syndromes
    • Myelodysplastic Syndromes Treatment (PDQ®)
    • MDS
    • Preleukemia
    • Bone marrow failure disorder

    ICD-10 Codes:

    • D469: Myelodysplastic syndrome, unspecified

    Does Dr. Natkunam accept my insurance?

    Dr. Natkunam accepts most major insurance plans. Important: Please call our office at (650) 723-7211 before your appointment to verify that your specific plan and network are accepted.

    What insurance plans does Dr. Natkunam accept in Pleasanton, CA?

    Dr. Natkunam in Pleasanton, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.

    Top Insurances

    • All Other Third Party

    • Blue Shield of California

    • Cigna Group

    • CVS Health (formerly Aetna)

    • Kaiser Permanente

    • Medicaid

    • Medicare

    • State of California

    • UnitedHealth Group

    • Unknown

    View All Insurances

    Where is Dr. Natkunam's office located?

    Dr. Yasodha Natkunam's Primary Practice

    5555 W Las Positas Blvd

    Pleasanton, CA 94588

    (650) 723-7211

    Get Directions

    Department Of Pathology

    300 Pasteur Dr

    Stanford, CA 94305

    Get Directions

    Recognitions

    Publications

    Germil centre protein HGAL promotes lymphoid hyperplasia

    , 2013

    Bevacizumab and cyclosphosphamide, doxorubicin

    , 2014

    Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte

    , 2014

    LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with

    , 2014

    Expression of the Activating Receptor, NKp46 (CD335), in Human tural Killer and T-Cell Neoplasia.

    , 2013

    Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal margil zone

    , 2013

    LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas

    , 2013

    CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma

    , 2013

    Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades

    , 2013

    Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma

    , 2013

    Usefulness of HGAL and LMO2 Immunohistochemistry in the Identification of Follicular Lymphomas of

    , 2013

    Indolent T-Lymphoblastic Proliferation (iT-LBP)

    , 2013

    The spectrum of lymphoblastic, nodal and extranodal T-cell lymphomas

    , 2013

    Syk-Induced Phosphatidylinositol

    , 2013

    Integration of Genomic Medicine into Pathology Residency Training The Stanford Open Curriculum

    , 2013

    Selective Immunophenotyping for Diagnosis of B-cell Neoplasms

    , 2013

    CD137 Ligand Is Expressed in Primary and Secondary Lymphoid Follicles and in B

    , 2013

    FHIT, EGFR, and MSH2

    Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients.

    TdT(+) T-lymphoblastic Populations Are Increased in Castleman Disease

    , 2012

    The contribution of HGAL

    , 2012

    Cyclin D3 coordites the cell cycle during differentiation to regulate erythrocyte size and number

    , 2012

    CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T

    , 2012

    Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma

    , 2012

    LIM domain only 2 protein expression, LMO2 germline genetic variation

    , 2012

    IgG4-Related Systemic Sclerosing Disease of the Ocular Adnexa A Potential Mimic of Ocular Lymphoma

    , 2012

    The spectrum of B-cell lymphoma, unclassifiable

    , 2012

    Aggressive EBV-associated Lymphoproliferative Disorder

    , 2012

    Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissue.

    , 2012

    Lack of association of tumor

    , 2012

    Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population

    , 2011

    Prediction of survival in diffuse large B

    , 2011

    Clinicopathologic and Molecular Features of 122 Brazilian Cases of Nodal and Extranodal NK

    , 2011

    MicroRs Are Independent Predictors of Outcome in Diffuse Large B

    , 2011

    LMO2 protein expression predicts survival in patients with rheumatoid arthritis

    , 2011

    HGAL Protein Expression Persists

    , 2011

    The Efficacy of HGAL and LMO2 in the Separation of Lymphom

    , 2011

    T-cell lymphomas: a tale of heterogeneity masking clarity

    , 2011

    Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte

    , 2010

    Oral and Extraoral Plasmablastic Lymphoma Similarities and Differences

    , 2010

    Immunoarchitectural Patterns in Follicular Lymphoma

    , 2010

    Expression of LMO2 Is Associated With t(14;18)

    , 2010

    Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma

    , 2010

    Embryonic Stem Cell-Derived Endothelial Cells Engraft Into the Ischemic Hindlimb

    , 2010

    C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia

    , 2010

    The inducible T-cell co-stimulator molecule is expressed on subsets of T cells

    , 2010

    Characterization of D-cyclin proteins in hematolymphoid neoplasms

    , 2010

    PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities

    , 2010

    CD81 protein is expressed at high levels in normal germil center B cells

    , 2010

    Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival

    , 2010

    Building tissue microarrays from suspension cells.

    , 2010

    Microtubule-associated Protein-2 is a Sensitive Marker of Primary and Metastatic Neuroblastoma

    , 2009

    Extracellular Sigl-Regulated Kise Positively Regulates the Oncogenic Activity of MCT

    , 2009

    Characterization of c

    , 2009

    Immunoarchitectural Patterns in Nodal Margil Zone B-Cell Lymphoma A Study of 51 Cases

    , 2009

    nofluidic proteomic assay for serial alysis of oncoprotein activation in clinical specimens

    , 2009

    Low Stage Follicular Lymphoma

    , 2009

    Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B

    , 2009

    The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms

    , 2009

    Gray zones around diffuse large B cell lymphoma

    , 2009

    Human germil center-associated lymphoma protein expression is associated with improved failure

    , 2009

    PTP1B is a negative regulator of interleukin 4-induced STAT6 sigling

    , 2008

    Immunohistochemical characterization of sal-type extranodal NK

    , 2008

    Tissue microarrays from bone marrow aspirates for high

    , 2008

    Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with

    , 2008

    Expression of HGAL in primary cutaneous large B-cell lymphomas

    , 2008

    Expression of the human germil-centre

    , 2008

    LMO2 protein expression predicts survival in patients with diffuse large B

    , 2008

    Prognostic significance of VEGF, VEGF receptors

    , 2008

    The Stanford Tissue Microarray Database

    , 2008

    Selective loss of B-cell phenotype in lymphocyte predomint Hodgkin lymphoma

    , 2007

    The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignt neoplasms

    , 2007

    Intertiol standardized approach for flow cytometric residual disease monitoring in chronic

    , 2007

    Oncogenic regulators and substrates of the aphase promoting complex

    , 2007

    Mast cell tryptase and microphthalmia transcription factor effectively discrimite cutaneous mast

    , 2007

    Microvessel density and expression of vascular endothelial growth factor and its receptors

    , 2007

    The oncoprotein LMO2 is expressed in normal germil-center B cells and in human B-cell lymphomas

    , 2007

    Expression of the R-binding protein VICKZ in normal hematopoietic tissues and neoplasms

    , 2007

    Expression of the human germil center-associated lymphoma

    , 2007

    The biology of the germil center.

    , 2007

    Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease

    , 2006

    EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis

    , 2006

    Jaw I/LRMP, a germil centre-associated marker for the immunohistological study of B-cell lymphomas

    , 2006

    Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice?

    , 2006

    The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas

    , 2006

    CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells

    , 2006

    Loss of CD19 expression in B-cell neoplasms

    , 2006

    Transmembrane adaptor molecules: a new category of lymphoid-cell markers

    , 2006

    Utility of syndecan-1

    , 2005

    Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma

    , 2005

    TMA-combiner, a simple software tool to permit alysis of replicate cores on tissue microarrays

    , 2005

    Cytologic diagnosis of Burkitt lymphoma.

    , 2005

    Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient

    , 2005

    Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine

    , 2005

    Expression of the human germil center-associated lymphoma (HGAL) protein

    , 2005

    Expression pattern of intracellular leukocyte

    , 2005

    Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas

    , 2005

    Expression of the bcl-6 and MUM1

    , 2005

    A novel method for making tissue microarrays from small numbers of suspension cells

    , 2005

    The NFATc1 transcription factor is widely expressed in white cells

    , 2005

    Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells

    , 2004

    Immunophenotypic and genotypic characterization of progression in follicular lymphomas

    , 2004

    Intracellular siglling molecules as immunohistochemical markers of normal

    , 2004

    Atypical cellular disorders.

    , 2004

    Characterization of variant patterns of nodular lymphocyte predomint Hodgkin lymphoma with

    , 2003

    Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report

    , 2003

    Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100

    What is Dr. Natkunam's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.

    Dr. Natkunam's National Provider Identifier (NPI) number is 1033261151.

    What common questions do patients ask about Dr. Natkunam?

    Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Natkunam

    What is Dr. Yasodha Natkunam's specialty?

    Dr. Natkunam is a Anatomic Pathologist & Clinical Pathologist near Pleasanton, CA.

    What does an Anatomic Pathologist & Clinical Pathologist do?

    A pathologist focuses on the causes and nature of diseases, contributing to diagnosis, prognosis, and treatment by applying knowledge from biological, chemical, and physical sciences in the laboratory. They utilize microscopic examinations of tissue specimens, cells, and body fluids, along with clinical laboratory tests on fluids and secretions, to diagnose, exclude, or monitor diseases.

    Is this Dr. Yasodha Natkunam affiliated with a ranked Castle Connolly Top Hospital?

    Yes, Dr. Natkunam is affiliated with Stanford Health Care - Stanford Hospital, Stanford Health Care - Valleycare, Alta Bates Summit Medical Center - Summit Campus, Ucsf Medical Center At Parnassus, Community Hospital Of Monterey Peninsula, Kaiser Permanente Oakland Medical Center which are a Castle Connolly Top Hospitals. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals

    When to see an Anatomic Pathologist & Clinical Pathologist?: Guides for symptoms, conditions, and treatments

    Understand your symptoms and know when it’s time to see an Anatomic Pathologist & Clinical Pathologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.

    Is Yasodha Natkunam accepting new patients in Pleasanton, CA?

    Yes, Dr. Yasodha Natkunam is accepting new patients at this time.

    Does Dr. Yasodha Natkunam offer online booking?

    Please contact Dr. Natkunam's office at (650) 723-7211 for information about online booking, telehealth, or to schedule an appointment.

    How can I make an appointment with Yasodha Natkunam?

    Please contact Dr. Natkunam's office at (650) 723-7211 for information regarding telehealth appointment availability or for scheduling assistance.

    Which board certifications does Dr. Yasodha Natkunam have?

    Dr. Yasodha Natkunam is certified by the American Board of Pathology.

    <section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>